Abstract
Allogeneic hematopoietic cell transplant (alloHCT) has emerged as a potential curative treatment for advanced non-Hodgkin’s lymphoma (NHL), especially for patients with chemorefractory disease, relapsed after prior autologous HCT and those with relapsed lymphoma who failed to collect adequate stem cells for autologous HCT. There are several phase II studies supported the role of alloHCT in low-grade lymphomas, but the data is scarce on the other subtypes of lymphomas. However, retrospective registries studies highlighted the inferior outcomes of alloHCT in aggressive lymphomas, with unacceptable higher relapse rate and non-relapse mortality when compared to low-grade lymphomas. Patients with chemorefractory disease and those with active disease at alloHCT had poor outcome. Therefore, incorporation of new target therapies to induce remission prior to transplant or as a bridge to alloHCT may lead to better outcome of alloHCT in NHL. Furthermore, well design prospective studies of alloHCT in NHL and employment of novel transplant approaches tailored toward specific histological subtype are urgently needed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Khouri IF, Saliba RM, Erwin WD et al (2012) Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119:6373–6378
Shea T, Johnson J, Westervelt P et al (2011) Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 17:1395–1403
Piñana JL, Martino R, Gayoso J et al (2010) Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 95:1176–1182
S Cohen, Kiss T, Lachance S et al (2012) Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant 18:951–957
Hari P, Carreras J, Zhang MJ et al (2008) Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 14:236–245
Avivi I, Montoto S, Canals C et al (2009) Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the lymphoma working party of the European group for blood and marrow transplantation. Br J Haematol 147:719–728
Thomson KJ, Morris EC, Milligan D et al (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28:3695–3700
Ito Y, Miyamoto T, Kamimura T et al (2013) Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the fukuoka blood and marrow transplantation group. Int J Hematol 98:463–471
Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545
Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184–4190
Bacher U, Klyuchnikov E, Le-Rademacher J et al (2012) Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 120:4256–4262
Lazarus HM, Zhang MJ, Carreras J et al (2010) A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 16:35–45
van Kampen RJ, Canals C et al (2011) Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European group for blood and marrow transplantation registry. J Clin Oncol 29:1342–1348
Rigacci L, Puccini B, Dodero A et al (2012) Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 91:931–939
Rezvani AR, Norasetthada L, Gooley T et al (2008) Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 143:395–403
Aksentijevich I, Jones RJ, Ambinder RF et al (2006) Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 12:965–972
Thomson KJ, Morris EC, Bloor A et al (2009) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 20(27):426–432
Sirvent A, Dhedin N, Michallet M et al (2010) Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the société française de greffe de moelle et de thérapie cellulaire. Biol Blood Marrow Transplant 16:78–85
Maramattom LV, Hari PN, Burns LJ et al (2013) Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 19:173–179
Cwynarski K, van Biezen A, de Wreede L et al (2012) Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party. J Clin Oncol 30:2211–2217
Villa D, Crump M, Panzarella T et al (2013) Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 31:1164–1171
Fenske TS, Zhang MJ, Carreras J et al (2014) Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 32:273–281
Hamadani M, Saber W, Ahn KW et al (2013) Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 19:625–631
Dietrich S, Boumendil A, Finel H et al (2014) Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the European group for blood and marrow transplantation (EBMT). Ann Oncol 25:1053–1058
Cook G, Smith GM, Kirkland K et al (2010) Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British society for blood and marrow transplantation. Biol Blood Marrow Transplant 16:1419–1427
Le Gouill S, Kröger N, Dhedin N et al (2012) Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23:2695–2703
Tam CS, Bassett R, Ledesma C et al (2009) Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144–4152
Maris MB, Sandmaier BM, Storer BE et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535–3542
Corradini P, Dodero A, Zallio F et al (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172–2176
Dodero A, Spina F, Narni F et al (2012) Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26:520–526
Smith SM, Burns LJ, van Besien K et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31:3100–3109
Kanakry JA, Kasamon YL, Gocke CD et al (2013) Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 19:602–606
Le Gouill S, Milpied N, Buzyn A et al (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 26:2264–2271
Kyriakou C, Canals C, Finke J et al (2009) Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27:3951–3958
Fukushima T, Miyazaki Y, Honda S et al (2005) Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19:829–834
Kato K, Kanda Y, Eto T, Muta T et al (2007) Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan marrow donor program. Biol Blood Marrow Transplant 13:90–99
Okamura J, Uike N, Utsunomiya A, Tanosaki R (2007) Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol 86:118–125
Murashige N, Kami M, Kishi Y et al (2005) Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 130:561–567
Duvic M, Donato M, Dabaja B et al (2010) Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28:2365–2372
Molina A, Zain J, Arber DA et al (2005) Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23:6163–6171
Duarte RF, Canals C, Onida F et al (2010) Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 28:4492–4499
Wu PA, Kim YH, Lavori PW et al (2009) A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant 15:982–990
Rodriguez R, Nademanee A, Ruel N et al (2006) Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12:1326–1334
Rodrigues CA, Rocha V, Dreger P et al (2014) Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 99:370–377
Castagna L, Boubdallah R, Furst S et al (2013) Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. Bone Marrow Transplant 48:794–798
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Aldoss, I., Nademanee, A. (2015). Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin’s Lymphomas. In: Evens, A., Blum, K. (eds) Non-Hodgkin Lymphoma. Cancer Treatment and Research, vol 165. Springer, Cham. https://doi.org/10.1007/978-3-319-13150-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-13150-4_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13149-8
Online ISBN: 978-3-319-13150-4
eBook Packages: MedicineMedicine (R0)